Patient Perspectives on Clotting in the Extracorporeal Circuit and Decision-Making Regarding Anticoagulation Therapy

Chandana Guha1, Daniel Gallego2, Amanda Grandinetti3

  • 1Centre for Kidney Research, Children's Hospital at Westmead, Sydney, Australia; Sydney School of Public Health, University of Sydney, Sydney, Australia.

Seminars in Nephrology
|January 17, 2024
PubMed

Insights

Understanding patient priorities in hemodialysis anticoagulation therapy is crucial. Shared decision-making can improve treatment adherence and outcomes for patients experiencing extracorporeal circuit clotting.

Area of Science:

  • Nephrology
  • Hematology
  • Patient Care

Background:

  • Extracorporeal circuit clotting is a significant complication during hemodialysis, leading to treatment interruptions and adverse patient outcomes.
  • Inadequate dialysis due to clotting can cause blood loss, fluid overload, mineral imbalances, increased hospitalizations, and reduced quality of life.
  • Anticoagulation therapy is vital for maintaining dialysis circuit patency and ensuring treatment adequacy.

Purpose of the Study:

  • To explore patients' perspectives and priorities regarding clotting and anticoagulation therapy in hemodialysis.
  • To identify strategies for supporting patients through shared decision-making in managing thrombotic complications.
  • To inform improved care strategies and patient outcomes in hemodialysis.

Main Methods:

  • Qualitative exploration of patient experiences and decision-making processes related to anticoagulation.
  • Discussion of patient priorities in the context of extracorporeal circuit clotting.
  • Analysis of insights to inform shared decision-making models.

Main Results:

  • Patient perspectives on anticoagulation therapy and clotting are not well understood.
  • Identifying patient priorities is key to effective anticoagulation management.
  • Shared decision-making can enhance patient engagement and treatment success.

Conclusions:

  • Understanding patient viewpoints on anticoagulation is essential for optimizing hemodialysis care.
  • Shared decision-making empowers patients and can mitigate the impact of clotting complications.
  • Incorporating patient priorities into treatment plans can improve hemodialysis adequacy and quality of life.

Related Concept Videos

Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
7.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
701
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.2K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
6.0K
Coagulation01:09

Coagulation

The coagulation phase is a critical part of the body's process to prevent blood loss following injury to blood vessels. It involves chemical reactions that form a clot to seal the injured area. The clotting process begins shortly after injury, within 15-20 seconds for severe damage and 1-2 minutes for minor injuries.
During the coagulation phase, clotting factors, or procoagulants, play a vital role in initiating and progressing the coagulation cascade. This cascade is a series of reactions...
6.7K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
525